Obesity Clinical Trial
Official title:
The Effects of Human-like Milk Oligosaccharide and Resistant Starch on Acetate Production and Human Substrate Metabolism
Verified date | March 2021 |
Source | Maastricht University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study investigators hypothesize (1) that the SCFA/acetate metabolism differs between metabolic phenotypes and (2) that using a mixture of fibres that differ in degree of polymerization and branching namely a resistant starch and a human-like milk oligosaccharide enhance the acetate availability in the distal colon and systemic circulation, consequently leading to its metabolic effects. To study this, the investigators will supplement lean, normoglycaemic vs. overweight/obese, prediabetic men with the fibre mixture the day before the clinical investigation day (CID) and study during the CID its effects on fasting and postprandial substrate and energy metabolism.
Status | Completed |
Enrollment | 19 |
Est. completion date | October 15, 2021 |
Est. primary completion date | October 15, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 30 Years to 65 Years |
Eligibility | Inclusion criteria: Lean (BMI = 20kg/m2 and = 24.9kg/m2) healthy men aged 30 - 65 years as well as overweight/obese (BMI = 25kg/m2 and = 34.9kg/m2) prediabetic men aged between 30 - 65 years Exclusion criteria: - Type 2 diabetes mellitus (defined as fasting plasma glucose = 7.1 mmol/L and 2h glucose = 11.1 mmol/L) - Gastroenterological diseases or abdominal surgery; - Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life expectancy shorter than 5 years; - Abuse of products; alcohol and drugs, excessive nicotine use defined as >20 cigarettes per day; - Plans to lose weight or following of a hypocaloric diet; - Regular supplementation of pre- or probiotic products, use of pre- or probiotics 3 months prior to the start of the study; - Intensive exercise training more than three hours a week; - Use of any medication that influences glucose or fat metabolism and inflammation (i.e. NSAIDs); - Regular use of laxation products; - Use of antibiotics in the last three months (antibiotics use can alter substantially the gut microbiota composition). - Follow a vegan diet. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Plasma acetate concentrations. | During the clinical investigation day plasma acetate will be sampled | plasma acetate will be sampled during the CID before the consumption of a liquid high fat mixed meal | |
Primary | Plasma acetate concentrations. | During the clinical investigation day plasma acetate will be sampled | plasma acetate will be sampled during the CID at t=60 minutes after consumption of a liquid high fat mixed meal | |
Primary | Plasma acetate concentrations. | During the clinical investigation day plasma acetate will be sampled | plasma acetate will be sampled during the CID at t=120 minutes after consumption of a liquid high fat mixed meal | |
Primary | Plasma acetate concentrations. | During the clinical investigation day plasma acetate will be sampled | plasma acetate will be sampled during the CID at t=240 minutes after consumption of a liquid high fat mixed meal | |
Primary | Faecal acetate concentrations. | On the day of clinical investigation day, fecal acetate will be sampled | Fecal acetate will be sampled in the morning before the testday | |
Primary | Plasma butyrate concentrations. | During the clinical investigation day, plasma butyrate will be sampled | plasma butyrate will be sampled during the CID before the consumption of a liquid high fat mixed meal | |
Primary | Plasma butyrate concentrations. | During the clinical investigation day, plasma butyrate will be sampled | plasma butyrate will be sampled during the CID at t=60 after consumption of a liquid high fat mixed meal | |
Primary | Plasma butyrate concentrations. | During the clinical investigation day, plasma butyrate will be sampled | plasma butyrate will be sampled during the CID at t=120 after consumption of a liquid high fat mixed meal | |
Primary | Plasma butyrate concentrations. | During the clinical investigation day, plasma butyrate will be sampled | plasma butyrate will be sampled during the CID at t=240 minutes after consumption of a liquid high fat mixed meal | |
Primary | Fecal butyrate concentrations. | On the day of clinical investigation day, fecal butyrate will be sampled | Fecal butyrate will be sampled in the morning before the testday | |
Primary | Plasma propionate concentrations. | During the clinical investigation day, plasma propionate will be sampled | Plasma propionate will be sampled during the CID before the consumption of a liquid high fat mixed meal | |
Primary | Plasma propionate concentrations. | During the clinical investigation day, plasma propionate will be sampled | Plasma propionate will be sampled during the CID t=60 minutes after the consumption of a liquid high fat mixed meal | |
Primary | Plasma propionate concentrations. | During the clinical investigation day, plasma propionate will be sampled | Plasma propionate will be sampled during the CID t=120 minutes after the consumption of a liquid high fat mixed meal | |
Primary | Plasma propionate concentrations. | During the clinical investigation day, plasma propionate will be sampled | Plasma propionate will be sampled during the CID t=240 minutes after the consumption of a liquid high fat mixed meal | |
Primary | Faecal propionate concentrations. | On the day of clinical investigation day, fecal propionate will be sampled | Fecal propionate will be sampled in the morning before the testday | |
Secondary | Energy expenditure, fat and carbohydrate oxidation | Energy expenditure, fat and carbohydrate oxidation will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands); | Indirect calorimetry will be measured before and for 4 hours after the consumption of the liquid high-fat mixed meal during the whole CID | |
Secondary | Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK). | Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK). | Breath H2 will be sampled during the CID before and at t=30, t=60, t=90, t=120 and t=240 minutes after consumption of a liquid high fat mixed meal | |
Secondary | Plasma glucose concentrations | Plasma glucose concentrations | Plasma glucose concentrations will be sampled during the CID before and t=0, t=30, t=60, t=120 and t=240 minutes after consumption of a liquid high fat mixed meal | |
Secondary | Plasma insulin concentrations | Plasma insulin concentrations | Plasma insulin concentrations will be sampled during the CID before and at t=0, t=30, t=60, t=120 and t=240 minutes after consumption of a liquid high fat mixed meal | |
Secondary | Plasma FFA concentrations | Plasma FFA concentrations | Plasma FFA concentrations will be sampled during the CID before and at t=0, t=30, t=60, t=120 and t=240 minutes after consumption of a liquid high fat mixed meal | |
Secondary | Faecal microbiota composition | Faecal microbiota composition will be assessed via16S rRNA gene sequencing | Faecal microbiota composition will be sampled in the morning before the testday |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |